Skip to content
PLYXPolaryx Therapeutics, Inc.

Earnings

When Polaryx Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

7 quarters. Mar 31, 2025 to Sep 30, 2026. mixed units.

Quarter by quarter

Q3 2026-$3.33MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 12, 2026, after the close
    Revenue
    —
    —
    Net income
    -$3.33M
    N/M
    EPS
    -$0.07
    N/M
  2. Q2 2026Aug 13, 2026, after the close+3.2%by the close of Aug 14
    Revenue
    —
    —
    Net income
    -$1.38M
    N/M
    EPS
    -$0.03
    N/M
  3. Q1 2026May 14, 2026, after the close21.7%by the close of May 15
    Revenue
    —
    —
    Net income
    -$2.54M
    N/M
    EPS
    -$0.05
    N/M
  4. Q4 2025Mar 23, 2026, after the close+16.7%by the close of Mar 24
    Revenue
    —
    —
    Net income
    -$1.50M
    —
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026—Nov 12, 202643 d10-Q——-$0.07—
Q2 2026Jun 30, 2026—Aug 13, 202644 d10-Q——-$0.03+3.2%
Q1 2026Mar 31, 2026—May 15, 202645 d10-Q——-$0.0521.7%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 24, 202683 d10-K———+16.7%
Q3 2025Sep 30, 2025——————-$0.03—
Q2 2025Jun 30, 2025——————-$0.02—
Q1 2025Mar 31, 2025——————-$0.11—

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026118950
10-QAug 13, 2026089118
10-QMay 15, 2026056973
10-KMar 24, 2026033064

Provenance

ProvenanceData status and checks

Polaryx Therapeutics, Inc. · CIK 2075320 · Engraved from SEC EDGAR